ECSP21071644A - Compuestos macrocíclicos como agonistas de sting - Google Patents
Compuestos macrocíclicos como agonistas de stingInfo
- Publication number
- ECSP21071644A ECSP21071644A ECSENADI202171644A ECDI202171644A ECSP21071644A EC SP21071644 A ECSP21071644 A EC SP21071644A EC SENADI202171644 A ECSENADI202171644 A EC SENADI202171644A EC DI202171644 A ECDI202171644 A EC DI202171644A EC SP21071644 A ECSP21071644 A EC SP21071644A
- Authority
- EC
- Ecuador
- Prior art keywords
- macrocyclic compounds
- sting agonists
- compounds
- disclosed
- macrocyclic
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 2
- 229940044665 STING agonist Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921012258 | 2019-03-28 | ||
| IN201921046194 | 2019-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21071644A true ECSP21071644A (es) | 2021-12-30 |
Family
ID=70293003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202171644A ECSP21071644A (es) | 2019-03-28 | 2021-09-24 | Compuestos macrocíclicos como agonistas de sting |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220144852A1 (es) |
| EP (1) | EP3946610A1 (es) |
| JP (1) | JP7530380B2 (es) |
| KR (1) | KR20210146370A (es) |
| CN (1) | CN113631228B (es) |
| AU (1) | AU2020245263B2 (es) |
| BR (1) | BR112021018947A2 (es) |
| CA (1) | CA3132508A1 (es) |
| CL (1) | CL2021002480A1 (es) |
| CO (1) | CO2021012559A2 (es) |
| CR (1) | CR20210495A (es) |
| EC (1) | ECSP21071644A (es) |
| IL (1) | IL286526A (es) |
| MA (1) | MA55517A (es) |
| MX (1) | MX2021011686A (es) |
| PE (1) | PE20220169A1 (es) |
| PH (1) | PH12021552263A1 (es) |
| SG (1) | SG11202109191SA (es) |
| WO (1) | WO2020194160A1 (es) |
| ZA (1) | ZA202106629B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20220937A1 (es) | 2019-07-22 | 2022-05-31 | Lupin Ltd | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos |
| CA3149482A1 (en) | 2019-08-02 | 2021-02-11 | Mersana Therapeutics, Inc. | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer |
| BR112022019919A2 (pt) | 2020-04-02 | 2023-02-14 | Mersana Therapeutics Inc | Conjugado de anticorpo-fármaco compreendendo agonistas de sting |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| WO2022155518A1 (en) * | 2021-01-15 | 2022-07-21 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| AR133266A1 (es) * | 2023-07-19 | 2025-09-10 | Hoffmann La Roche | Macrociclos para el tratamiento de enfermedades autoinmunitarias |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| JP6835727B2 (ja) * | 2015-02-05 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用 |
| EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| KR20180132783A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
| CN113549110B (zh) * | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| CA3067257A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| JP2020524717A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの小分子調節因子 |
| WO2019023635A1 (en) | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
| AU2018311965A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
-
2020
- 2020-03-21 MA MA055517A patent/MA55517A/fr unknown
- 2020-03-21 BR BR112021018947A patent/BR112021018947A2/pt unknown
- 2020-03-21 SG SG11202109191SA patent/SG11202109191SA/en unknown
- 2020-03-21 WO PCT/IB2020/052654 patent/WO2020194160A1/en not_active Ceased
- 2020-03-21 EP EP20719719.5A patent/EP3946610A1/en active Pending
- 2020-03-21 CN CN202080025785.1A patent/CN113631228B/zh active Active
- 2020-03-21 KR KR1020217035108A patent/KR20210146370A/ko not_active Ceased
- 2020-03-21 MX MX2021011686A patent/MX2021011686A/es unknown
- 2020-03-21 PE PE2021001577A patent/PE20220169A1/es unknown
- 2020-03-21 AU AU2020245263A patent/AU2020245263B2/en active Active
- 2020-03-21 CR CR20210495A patent/CR20210495A/es unknown
- 2020-03-21 CA CA3132508A patent/CA3132508A1/en active Pending
- 2020-03-21 PH PH1/2021/552263A patent/PH12021552263A1/en unknown
- 2020-03-21 US US17/598,524 patent/US20220144852A1/en active Pending
- 2020-03-21 JP JP2021557830A patent/JP7530380B2/ja active Active
-
2021
- 2021-09-08 ZA ZA2021/06629A patent/ZA202106629B/en unknown
- 2021-09-19 IL IL286526A patent/IL286526A/en unknown
- 2021-09-24 CL CL2021002480A patent/CL2021002480A1/es unknown
- 2021-09-24 EC ECSENADI202171644A patent/ECSP21071644A/es unknown
- 2021-09-24 CO CONC2021/0012559A patent/CO2021012559A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113631228A (zh) | 2021-11-09 |
| SG11202109191SA (en) | 2021-09-29 |
| MA55517A (fr) | 2022-02-09 |
| JP7530380B2 (ja) | 2024-08-07 |
| CO2021012559A2 (es) | 2021-09-30 |
| CA3132508A1 (en) | 2020-10-01 |
| AU2020245263B2 (en) | 2025-07-03 |
| PH12021552263A1 (en) | 2022-07-11 |
| AU2020245263A1 (en) | 2021-10-07 |
| JP2022527306A (ja) | 2022-06-01 |
| EP3946610A1 (en) | 2022-02-09 |
| CR20210495A (es) | 2021-10-18 |
| MX2021011686A (es) | 2021-10-22 |
| US20220144852A1 (en) | 2022-05-12 |
| IL286526A (en) | 2021-10-31 |
| BR112021018947A2 (pt) | 2022-02-08 |
| CL2021002480A1 (es) | 2022-04-29 |
| KR20210146370A (ko) | 2021-12-03 |
| CN113631228B (zh) | 2023-10-13 |
| ZA202106629B (en) | 2022-07-27 |
| WO2020194160A1 (en) | 2020-10-01 |
| PE20220169A1 (es) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001814A2 (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| CO2021012559A2 (es) | Compuestos macrocíclicos como agonistas de sting | |
| CL2022001625A1 (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| UY40230A (es) | Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX367404B (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco | |
| MX2021011007A (es) | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. | |
| AR132461A2 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| MX2020005341A (es) | Azaciclos sustituidos como moduladores alostericos positivos del receptor m1 muscarinico. |